Holen Sie sich die Stockscreener-App
6.85
1.86%
-0.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.98
Offen:
$7.14
24-Stunden-Volumen:
1.20M
Relative Volume:
1.02
Marktkapitalisierung:
$734.49M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-191.78M
KGV:
-3.5191
EPS:
-1.9465
Netto-Cashflow:
$-172.86M
1W Leistung:
-6.04%
1M Leistung:
-33.40%
6M Leistung:
-8.54%
1J Leistung:
+19.34%
1-Tages-Spanne:
$6.78
$7.26
1-Wochen-Bereich:
$6.78
$7.54
52-Wochen-Spanne:
$3.79
$11.45
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.85 | 781.67M | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Guggenheim | Buy |
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences is a speculative buy with pro... - Pluang
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB) - Seeking Alpha
New data from Solid Biosciences to be shared at neuromuscular research event - Traders Union
Solid Biosciences stock edges lower as investors weigh recent gains and fundamentals - AD HOC NEWS
Solid Biosciences stock gains on fresh analyst upgrades and DMD outlook - AD HOC NEWS
Solid Biosciences Inc.Common Stock (Nasdaq:SLDB) Detailed Stock Data - The Chronicle-Journal
Solid Biosciences stock gains on analyst upgrade and growing gene therapy pipeline - AD HOC NEWS
Solid Biosciences wins new Outperform at RBC on DMD opportunity - Seeking Alpha
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says - Yahoo Finance
Leerink Partners Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
SLDB Initiated Coverage by RBC Capital -- Rating Set at Outperfo - GuruFocus
RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target - marketscreener.com
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - kalkine.com.au
SLDB: Advancing novel gene therapies for DMD and FA, with pivotal FDA meetings and data ahead - TradingView
SLDB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Solid Biosciences stock rating at buy By Investing.com - Investing.com Canada
Solid Biosciences at Citi summit: FDA tests loom for gene therapy push - Investing.com Canada
Solid Biosciences Q2 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipProfit Growth Outlook - dars.gov.et
Solid Biosciences at Cantor Fitzgerald conference: 2025 catalyst push By Investing.com - Investing.com India
SLDB: Pivotal gene therapy data and regulatory milestones for DMD and FA expected in early 2025 - TradingView
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
Cantor raises Solid Biosciences stock price target on gene therapy - Investing.com
Cantor raises Solid Biosciences stock price target on gene therapy By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Solid Biosciences(SLDB.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Daniel Fischer and Ilan Ganot: The Parent-CEOs Who Turned Their Children's Diagnoses into Biotech Missions - finance.biggo.com
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SLDB Maintained by Truist Securities -- Price Target Raised to $20 - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Financial Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $20 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7%Time to Sell? - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Solid Biosciences Inc. brings patient advocates to FA panel at GMP Lab - Traders Union
Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits - Stock Titan
Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares - Stock Titan
Solid Biosciences (SLDB) Holds Steady Near $9.09 as Gene Therapy Sector Watches Key LevelsVolume Weighted Price - vinanet.vn
HC Wainwright Has Positive Estimate for SLDB Q3 Earnings - MarketBeat
Form 8K Solid Biosciences LLC For: 6 August By Investing.com - Investing.com Nigeria
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citizens reiterates Solid Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on pipeline progress - Investing.com
SLDB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage CostsProfit Cycle Analysis - careplusvn.com
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Solid Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Solid Biosciences Inc. Stock 12‑Month Price Target Cut to $17.64, Implies 102% Upside - TradingView
Solid Biosciences Inc (SLDB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):